

Alfasigma – Withdrawal of Zelnorm[®] (tegaserod)

- On June 28, 2022, <u>Alfasigma announced</u> that <u>Zelnorm (tegaserod)</u> will be withdrawn from the market. The discontinuation is a business decision and is not due to safety, quality or efficacy issues, or any recall imposed on the product.
- Zelnorm is indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C).

Product Description	NDC#
Zelnorm (tegaserod) 6 mg tablets	00525-0971-60

- Other medications indicated for the treatment of IBS-C include brand and generic <u>Amitiza®</u> (<u>lubiprostone</u>), brand <u>Linzess® (linaclotide</u>), and brand <u>Trulance® (plecanatide</u>).
- Patients should contact their physician or health care provider if they have any questions regarding their Zelnorm therapy.
 - 0.019). Over the course of the study, the event rate (percentage of patients per year) was 33.6% with Verquvo vs. 37.8% with placebo.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.